➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Harvard Business School
Express Scripts
Mallinckrodt

Last Updated: March 8, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Avigan

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Avigan?

Avigan is an investigational drug.

There have been 16 clinical trials for Avigan. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.

The most common disease conditions in clinical trials are Hemorrhagic Fever, Ebola, Respiratory Distress Syndrome, Adult, and Severe Acute Respiratory Syndrome. The leading clinical trial sponsors are Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti, and Institut National de la Santé Et de la Recherche Médicale, France.

There are one hundred and twenty-six US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Avigan
TitleSponsorPhase
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma TherapyKoja Regional Public HospitalPhase 1/Phase 2
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma TherapyHayandra Peduli FoundationPhase 1/Phase 2
Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting ConditionsNovagenix Bioanalytical Drug R&D CenterPhase 1

See all Avigan clinical trials

Clinical Trial Summary for Avigan

Top disease conditions for Avigan
Top clinical trial sponsors for Avigan

See all Avigan clinical trials

US Patents for Avigan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Avigan   Start Trial Methods and compositions for inhibition of polymerase BioCryst Pharmaceuticals, Inc. (Durham, NC)   Start Trial
Avigan   Start Trial Methods of preparing inhibitors of influenza viruses replication Vertex Pharmaceuticals Incorporated (Boston, MA)   Start Trial
Avigan   Start Trial Viral prophylaxis treatment methods and pre-exposure prophylaxis kits ELIAN LLC (Monrovia, CA)   Start Trial
Avigan   Start Trial Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. (South San Francisco, CA)   Start Trial
Avigan   Start Trial Potent anti-influenza A neuraminidase subtype N1 antibody The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Avigan

Drugname Country Document Number Estimated Expiration Related US Patent
Avigan Australia AU2011315902 2030-10-15   Start Trial
Avigan Australia AU2017200471 2030-10-15   Start Trial
Avigan Brazil BR112013009029 2030-10-15   Start Trial
Avigan Canada CA2813783 2030-10-15   Start Trial
Avigan China CN103429245 2030-10-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Harvard Business School
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.